UGCG Antibody (1E5): sc-293235

UGCG Antibody (1E5) is a mouse monoclonal IgG1 kappa light chain antibody that detects UGCG protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-UGCG antibody (1E5) is available as the non-conjugated format. UGCG protein, also known as glucosylceramide synthase, plays a crucial role in glycosphingolipid biosynthesis, catalyzing the initial glycosylation step by transferring glucose to ceramide. This enzymatic activity is vital for various cellular processes, including cell recognition, proliferation, differentiation, and immune responses. Glucosylceramide synthase is predominantly located in the plasma membrane and Golgi complex of eukaryotic cells, where enzymatic activity is essential for maintaining cellular homeostasis and signaling pathways. Dysregulation of UGCG has been linked to several pathological conditions, including lysosomal storage disorders and cancer, making UGCG a significant target for therapeutic interventions. UGCG (1E5) antibody effectively detects UGCG across multiple species, enhancing research utility in understanding molecular mechanisms underlying these diseases and potential for drug-induced apoptosis in various cell types.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

UGCG Antibody (1E5) References:

1. Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells.  |  Uchida, Y., et al. 2004. Cancer Res. 64: 6271-9. PMID: 15342415
2. Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions.  |  Hakomori, S. 1990. J Biol Chem. 265: 18713-6. PMID: 2229037
3. The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1).  |  Wegner, MS., et al. 2018. BMC Cancer. 18: 153. PMID: 29409484
4. UGCG influences glutamine metabolism of breast cancer cells.  |  Schömel, N., et al. 2019. Sci Rep. 9: 15665. PMID: 31666638
5. UGCG overexpression leads to increased glycolysis and increased oxidative phosphorylation of breast cancer cells.  |  Schömel, N., et al. 2020. Sci Rep. 10: 8182. PMID: 32424263
6. Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition.  |  Jain, V., et al. 2023. Cancer Discov. 13: 454-473. PMID: 36331284
7. UGCG modulates heart hypertrophy through B4GalT5-mediated mitochondrial oxidative stress and the ERK signaling pathway.  |  Cui, S., et al. 2023. Cell Mol Biol Lett. 28: 71. PMID: 37658291
8. UGCG promotes chemoresistance and breast cancer progression via NF-κB and Wnt/β-catenin pathway activation.  |  Long, L., et al. 2025. Transl Oncol. 52: 102241. PMID: 39674092
9. Purification and characterization of UDP-glucose:ceramide glucosyltransferase from rat liver Golgi membranes.  |  Paul, P., et al. 1996. J Biol Chem. 271: 2287-93. PMID: 8567691
10. Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis.  |  Ichikawa, S., et al. 1996. Proc Natl Acad Sci U S A. 93: 4638-43. PMID: 8643456
11. Up-regulation of glucosylceramide synthase expression and activity during human keratinocyte differentiation.  |  Watanabe, R., et al. 1998. J Biol Chem. 273: 9651-5. PMID: 9545298
12. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells.  |  Liu, YY., et al. 1999. J Biol Chem. 274: 1140-6. PMID: 9873062

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-UGCG Antibody (1E5) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-UGCG Antibody (1E5) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

UGCG Antibody (1E5) Specifications

Alternate Product Name: UGCG

Product Clone Name: 1E5

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 33-131

Epitope Target: UGCG

Epitope Species: human

Product Reactivity/Detection: UGCG

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for UGCG Antibody (1E5): N/A